Noxopharm announces new CEO ahead of growth phase

Pharma News: Australian clinical-stage drug development company Noxopharm announced an executive transition which places the Company in a great position to move into the next phase of its growth and expansion.

Dr Gisela Mautner will be appointed as the Chief Executive Officer from 1 February 2022, with Dr Graham Kelly remaining on the Board as a Non-Executive Director and shifting from an executive to a consultant role. Dr Mautner, currently the Company’s Chief Medical Officer, also will serve on the Board as Executive Managing Director.

Noxopharm CEO, Dr Kelly, said “The Company is in the process of transiting from an early-stage biotech company into a serious biopharma company looking to make its mark on the world stage. I made the decision several months ago that 2022 was the time for a generational change and time to hand over to someone with large pharma industry experience who could oversee the Company position itself as a valuable partnering opportunity. Having worked alongside Gisela for several years now, I have full confidence in her ability to achieve that objective. I believe she will make an outstanding CEO.

Dr Mautner, who is also the past President of the Australian Pharmaceutical medical and scientific Professionals Association (APPA), said “Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the Company through its next stages. I look forward to working with the Board and the talented team at Noxopharm to deliver success and value for our many stakeholders. A new Department Head is being appointed to oversee the delivery of our Clinical Development Program.”

You may also like: Cancer patients hit hard by cuts to telehealth rebates

Noxopharm Non-Executive Chairman, Mr Fred Bart, commented “Graham has, with the full support of the Board, chosen to transition from the CEO/MD role and has accepted the Board’s invitation to continue as a non-executive director and as a consultant to support Gisela as required. The Board would like to thank Graham for his unrelenting dedication and commitment to Noxopharm and welcomes his ongoing contribution. The Board regards Gisela as an outstanding successor and is confident in her ability to create and advance significant shareholder value in the years ahead.”

Dr Kelly added “As the Company’s largest shareholder, ongoing Board member and Inventor of much of the Company’s intellectual property, I intend to remain actively involved in the Company’s future.”